Real‐world treatment of large B‐cell lymphoma with chimeric antigen receptor T‐cell therapy after loncastuximab tesirine

Documenti analoghi

• Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
  di: Joshua Mehr, et al.
  Pubblicazione: (2024)
• Fluctuation of physical function during chimeric antigen receptor T‐cell therapy during rehabilitation intervention: Real‐world data and risk factor analyses
  di: Ryota Hamada, et al.
  Pubblicazione: (2024)
• Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England
  di: Christopher P. Fox, et al.
  Pubblicazione: (2024)
• B‐cell maturation antigen expression and clinical features of plasmablastic lymphoma
  di: Ning Dong, et al.
  Pubblicazione: (2024)
• Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B‐cell lymphoma in an adolescent patient
  di: Dasom Lee, et al.
  Pubblicazione: (2024)